The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma.

abstract：:Intra-arterial (IA) therapies for hepatocellular carcinoma (HCC) are considered palliative and should be offered to patients with intermediate-stage multinodular disease and with sufficient liver reserve. They include transarterial chemoembolization (TACE) or bland embolization, transarterial chemotherapy, and transar...

journal_title：Seminars in oncology

authors： Tsochatzis EA,Germani G,Burroughs AK

更新日期：2010-04-01 00:00:00

abstract：:The liver is the most common site of metastatic colorectal cancer (CRC) and the status of this organ is an important determinant of overall survival in patients with advanced disease. Complete resection of hepatic CRC metastases can provide a long-term cure for some patients, but the majority of liver metastases are n...

journal_title：Seminars in oncology

authors： Ruan DT,Warren RS

更新日期：2005-02-01 00:00:00

abstract：:We report the updated results of an intensive treatment protocol for children (< 18 years) and adults (> or = 18 years) with advanced B-cell lymphomas. The protocol consists of two chemotherapy regimens: A, consisting of cyclophosphamide, doxorubicin, vincristine and high-dose methotrexate (CODOX-M), and B, consisting...

journal_title：Seminars in oncology

authors： Adde M,Shad A,Venzon D,Arndt C,Gootenberg J,Neely J,Nieder M,Owen W,Seibel N,Wilson W,Horak ID,Magrath I

更新日期：1998-04-01 00:00:00

abstract：:To improve the resectability and long-term local control of locally advanced rectal cancer, we have initiated a radiation dose-escalation trial. It is hoped that the radioprotector amifostine will sufficiently reduce rectal morbidity (without also reducing tumor response) to permit increasing radiation doses. Only 6 p...

journal_title：Seminars in oncology

authors： Myerson R,Zobeiri I,Birnbaum E,Dietz D,Fleshman J,Kodner I,Picus J,Ratkin G

更新日期：2002-12-01 00:00:00

abstract：:Bone marrow transplantation (BMT) preparative regimens consisting of busulfan (Bu) and cyclophosphamide (Cy) were developed as an alternative to preparative regimens based on total body irradiation (TBI). Animal studies demonstrated that Bu had a high level of myeloablative and antileukemic activity, but little immuno...

journal_title：Seminars in oncology

authors： Santos GW

更新日期：1993-08-01 00:00:00

abstract：:Colorectal cancer is the third most common cause of cancer-related death in both men and women. Surgery is the primary form of treatment, with greater than 90% of patients surviving 5 years or more. The remaining patients have metastatic disease, for which treatment options are limited. The fluoropyrimidine, 5-fluorou...

journal_title：Seminars in oncology

authors： Creemers GJ

更新日期：1997-12-01 00:00:00

abstract：:Carboplatin is one of the most active agents in untreated small cell lung cancer (SCLC) (11% complete response [CR], 59% CR plus partial response [PR]). Combination carboplatin/etoposide/vincristine (CEV) (phase II trial) led to an overall remission rate of 84% in patients with limited disease (LD), with 52% CRs. The ...

journal_title：Seminars in oncology

authors： Gatzemeier U,Hossfeld DK,Neuhauss R,Reck M,Achterrath W,Lenaz L

更新日期：1992-02-01 00:00:00

abstract：:Monoclonal antibodies (mAbs) and their directly derived cell-based application known as chimeric antigen receptors (CARs) ensue from the need to develop novel therapeutic strategies that retain high anti-tumor activity, but carry reduced toxicity compared to conventional chemo- and radiotherapies. In this concise revi...

journal_title：Seminars in oncology

authors： Caruana I,Diaconu I,Dotti G

更新日期：2014-10-01 00:00:00

abstract：:This phase I trial was designed to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin (400 mg/m2) as first-line chemotherapy for stage IIIC/IV ovarian adenocarcinoma. After premedication, paclitaxel was infu...

journal_title：Seminars in oncology

authors： Lhommé C,Kerbrat P,Lejeune C,Guastalla JP,Fumoleau P,Goupil A,Héron JF,Cassin MA,Pruvot I,Soares JA,Chazard M

更新日期：1996-10-01 00:00:00

abstract：:During the past decade, local control of primary sarcomas of the extremities by radiation and conservative surgery has supplanted more radical compartmental resections or amputations. Reviews of others and our published data show that the probability of achieving local control is highly dependent on achieving negative...

journal_title：Seminars in oncology

authors： Spiro IJ,Gebhardt MC,Jennings LC,Mankin HJ,Harmon DC,Suit HD

更新日期：1997-10-01 00:00:00

abstract：:Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer, often presenting with distant metastasis. While controversy exists regarding the actual incidence of the disease, there is agreement that IBC causes a disproportionate number of breast cancer deaths. Those with typical IBC symptoms face a h...

journal_title：Seminars in oncology

authors： Mason G,Johnson O

更新日期：2008-02-01 00:00:00

abstract：:Myeloid neoplasms are characterized by acquired somatic mutations and epigenetic alterations in genes that are crucial for hematopoietic differentiation and cellular proliferation and survival pathways. The heterogeneity and genetic complexity of these disorders is daunting, but the improvement in our knowledge of the...

journal_title：Seminars in oncology

authors： Odenike O,Thirman MJ,Artz AS,Godley LA,Larson RA,Stock W

更新日期：2011-04-01 00:00:00

abstract：:A dose-response relationship has long been suspected for progestin compounds in the treatment of breast cancer, but only recently have trials been implemented to investigate this issue. In 1985, we began a phase I-II study of high-dose megestrol acetate in dosages of 480 mg/d to 1,600 mg/d in heavily pretreated postme...

journal_title：Seminars in oncology

authors： Tchekmedyian NS,Tait N,Abrams J,Aisner J

更新日期：1988-04-01 00:00:00

abstract：:The options available to patients with advanced non-small cell lung cancer (NSCLC) resistant or refractory to first-line chemotherapy are very limited. The older-generation drugs (etoposide, vindesine, epirubicin, and cisplatin) that are active against previously untreated NSCLC do not achieve a response rate greater ...

journal_title：Seminars in oncology

authors： Belani CP

更新日期：1998-06-01 00:00:00

abstract：:At Indiana University, we began clinical trials with ifosfamide in 1981. Although our initial efforts were in a variety of tumor types, including pancreatic cancer, we have most recently focused our attention on two tumors that have historically exhibited a higher degree of chemosensitivity--testicular cancer and smal...

journal_title：Seminars in oncology

authors： Loehrer PJ,Williams SD,Nichols CR,Einhorn LH

更新日期：1992-02-01 00:00:00

abstract：:Bendamustine has clinical potential in the treatment of low-grade non-Hodgkin's lymphoma (NHL). As a single agent, bendamustine has been used in two studies in patients with relapsed or refractory low-grade NHL. When bendamustine 120 mg/m(2) was given on days 1 and 2, the overall response rate was 73% with complete re...

journal_title：Seminars in oncology

authors： Rummel MJ,Mitrou PS,Hoelzer D

更新日期：2002-08-01 00:00:00

abstract：:Squamous cell carcinoma of the head and neck remains a clinical challenge because of the high rate of locoregional disease recurrence. The importance of the epidermal growth factor receptor (EGFR) in the development and progression of many solid tumors, including squamous cell carcinoma of the head and neck, is well u...

journal_title：Seminars in oncology

authors： Herbst RS,Hong WK

更新日期：2002-10-01 00:00:00

abstract：:Vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Medicament, Paris, France), a semisynthetic vinca alkaloid, and ifosfamide have each shown activity as a single agent and in various combination-chemotherapy regimens against non-small cell lung cancer. Vinorelbine usually has been...

journal_title：Seminars in oncology

authors： Masters GA,Hoffman PC,Drinkard LC,Watson S,Samuels BL,Golomb HM,Vokes EE

更新日期：1996-04-01 00:00:00

abstract：:Over the last 40 years the National Cancer Institute (NCI) has created a vibrant public-private partnership for the implementation of NCI-sponsored cooperative group (Network) clinical trials throughout the United States and Canada. Over these four decades, the cancer clinical trials process has become more complex mo...

journal_title：Seminars in oncology

authors： Lloyd Wade J 3rd,Petrelli NJ,McCaskill-Stevens W

更新日期：2015-10-01 00:00:00

abstract：:Inflammatory breast cancer (IBC) is an extremely aggressive disease that progresses rapidly and carries a very grim prognosis. It is characterized by erythema, rapid enlargement of the breast, skin ridging, and a characteristic peau d'orange appearance of the skin secondary to dermal lymphatic tumor involvement. Altho...

journal_title：Seminars in oncology

authors： Singletary SE,Cristofanilli M

更新日期：2008-02-01 00:00:00

abstract：:Richter syndrome (RS) is the development of an aggressive lymphoma in patients with a previous or concomitant diagnosis of chronic lymphocytic leukemia (CLL). The incidence rate RS is ~0.5% per year of observation. Two biomarkers (NOTCH1 mutations and subset 8 configuration of the B-cell receptor) may help identifying...

journal_title：Seminars in oncology

authors： Rossi D,Gaidano G

更新日期：2016-04-01 00:00:00

abstract：:Hepatic metastases are a major cause of morbidity and mortality for patients with colorectal cancer (CRC). The rationale for hepatic arterial chemotherapy has both an anatomical and pharmacological basis. Several randomized clinical studies of fluoropyrimidine showed higher response rates in all trials when the drug w...

journal_title：Seminars in oncology

authors： Kemeny NE,Ron IG

更新日期：1999-10-01 00:00:00

abstract：:Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has shown in vitro and clinical activity against non-small cell lung cancer and astrocytic brain tumors, tumors traditionally thought of as relatively resistant to chemotherapy and radiotherapy. Because of its ability to block dividing cells in the G2/M p...

journal_title：Seminars in oncology

authors： Glantz MJ,Choy H,Akerley W,Kearns CM,Egorin MJ,Rhodes CH,Cole BF

更新日期：1996-12-01 00:00:00

abstract：:Based on rigorous interpretation of current evidence, systemic therapy has two roles in the management of carcinoma of the uterine cervix. In patients with advanced or recurrent disease, single-agent chemotherapy constitutes the treatment of choice. The most extensively studied agents are the platinum compounds. Eithe...

journal_title：Seminars in oncology

authors： Thigpen T,Vance RB,Khansur T

更新日期：1994-04-01 00:00:00

abstract：:Etoposide has proven to be an active agent in the treatment of a variety of neoplasms, particularly germ cell cancers and small cell lung cancer. Yet despite its widespread use, the optimal dose and schedule for etoposide remain unknown. The fact that its efficacy appears to be schedule dependent, along with the recen...

journal_title：Seminars in oncology

authors： Loehrer PJ Sr

更新日期：1992-12-01 00:00:00

abstract：:Multiple myeloma (MM) is a heterogeneous disease for which several new treatments are available. Much has been learned about its biology over the past 15 years. We now understand that there are various subtypes of the disease, each one associated with different outcomes and clinical pathological features. While a deta...

journal_title：Seminars in oncology

authors： Fonseca R,Monge J

更新日期：2013-10-01 00:00:00

abstract：:With the increasing numbers of breast cancers survivors, menopause, its symptoms, and its physical complications are becoming more prevalent problems in this patient population. Hormonal replacement, which has been the cornerstone therapy of menopausal related symptoms for decades, recently has been shown to increase ...

journal_title：Seminars in oncology

authors： Bruno D,Feeney KJ

更新日期：2006-12-01 00:00:00

abstract：:Experimental renal-cell carcinoma can be induced by many different chemical carcinogens; dimethyl nitrosoamine has been most studied. The disease so induced in experimental animals closely resembles the spontaneous disease in man in histopathology, course, and other characteristics. Two agents that are probably etiolo...

journal_title：Seminars in oncology

authors： Outzen HC,Maguire HC Jr

更新日期：1983-12-01 00:00:00

abstract：:Pancreatic cancer is the eighth most common cancer in Europe, accounting for 4.1% of cancer deaths in men and 4.8% in women. Standardized pancreatoduodenectomy and left pancreatectomy are the gold standard for routine surgical treatment of pancreatic cancer. Total pancreatectomy should be reserved for positive pancrea...

journal_title：Seminars in oncology

authors： Pedrazzoli S,Pasquali C,Sperti C

更新日期：2002-12-01 00:00:00

abstract：:The optimal management of early stage ovarian cancer with poor prognostic features remains controversial. On the basis of results of studies in advanced ovarian cancer, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in combination with a platinum agent has become part of adjuvant chemotherapy trials i...

journal_title：Seminars in oncology

authors： Young RC

更新日期：2000-06-01 00:00:00